Smart Matrix® has been tested in a clinical trial for the treatment of full thickness surgical wounds resulting from the excision of non-malignant skin cancers. The results from this study demonstrated the safety, tolerability and performance of Smart Matrix® and, most importantly, offered the prospect of healing such wounds without a skin graft.
We aim to extend the application of Smart Matrix® to other acute full thickness wounds such as burns and trauma injuries. We have preliminary pre-clinical data to suggest that Smart Matrix® will perform well in these indications.
Chronic wounds, such as diabetic and venous leg ulcers are a large, and due to an ageing population, growing healthcare problem. Long-term unhealed wounds are painful, debilitating and can lead to amputation. Given the positive results obtained using Smart Matrix® for the treatment of acute wounds we predict it could play a similar role in promoting the healing of chronic wounds. We are working on methods to slightly modify the composition and physical properties of Smart Matrix® to optimise its potential to treat these debilitating wounds.
The physical scaffold properties of Smart Matrix®, in particular its ability to support new blood vessel formation, has the potential to open up many other exciting applications outside wound healing. We are actively pursuing such applications, including the combination of Smart Matrix® with stem cells to generate a composite product for reconstructive surgeries and its combination with other biomaterials to generate novel scaffolds for applications such as bone regeneration.
Smart Matrix Limited - Winners of the 2016 International Life Sciences Award for Best Medical Implant & Technology Research Group
Smart Matrix Limited – Winner of the 2016 ACQ5 Global Award for UK Gamechanger of the Year – Ms Leonor Stjepic
Smart Matrix Limited – Winner of the 2016 ACQ5 Global Award for UK - Company of the Year
Smart Matrix Limited – Winner of the 2016 Healthcare and Life Sciences Award